Skip to main content
Caplight Logo









Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc.

Public

Faeth Therapeutics, Inc. is now publicly traded

The data on this page reflects Faeth Therapeutics, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

PIPE

Feb 17, 2026

Est. Valuation at Exit

$368.32M

Total Funding Raised

$292M

Company Overview

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company that develops precision therapies and nutritional interventions for cancer treatment.

Sector

Biotech

Verticals

Life Sciences, Oncology

AI Layer

Infrastructure

Keywords

precision oncologymetabolic therapycancer metabolismnutrient controldrug discoveryMetabOScomputational biologysolid tumor therapymetabolic interventioncancer researchbiotechmetabolic medicinenutritional oncologyclinical trialscancer starvation

Faeth Therapeutics, Inc. Comparables

Compare Faeth Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Faeth Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Polaris Group
77%
StageZero Life Sciences Ltd.
73%
ImmunoMet Therapeutics
71%

Faeth Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPEFeb 17, 2026
VC RoundOct 20, 2025
Series AJun 30, 2022
SeedJan 18, 2022

Key People

Founding team and executive leadership

Anand Parikh

Chief Executive Officer & Founder

Founding Team

Brian Stephenson

CFO at Faeth Therapeutics

Executive Team

Faeth Therapeutics, Inc. Investors

Notable investors and investment history

Faeth Therapeutics, Inc. investors
InvestorRounds
Balyasny Asset Management L.P.PIPE
RA Capital ManagementPIPE
Future VenturesSeries A, VC Round, Seed
Columbia Threadneedle InvestmentsPIPE
Fairmount Funds ManagementPIPE
Digitalis VenturesSeries A, VC Round, Seed
B Capital GroupVC Round

Recent news

Latest coverage and updates

  • is_developingSep 18, 2026

    Faeth Therapeutics Inc. is developing FTX-249 on Sep 18th '26.

  • is_developingAug 18, 2026

    Faeth Therapeutics Inc. is developing Study FTH-PIK-201 on Aug 18th '26.

  • attends_eventAug 7, 2026

    Faeth Therapeutics Inc. attended event Upcoming Scientific Conference on Aug 8th '26.

Faeth Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Faeth Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersAustin, Texas
Employee Range32
Year Founded2019
Last FundingFeb 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?